Mass Balance and Absolute Oral Bioavailability of [14C]VH4524184

2026-525590-40-00 Protocol 223803 Human pharmacology (Phase I) - Other Ongoing, recruiting

Start 3 Jun 2026 · Status Ongoing, recruiting · 1 EU/EEA countries · 1 sites · Protocol 223803

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - Other
Status Ongoing, recruiting
Participants planned 9
Countries 1
Sites 1

human immunodeficiency virus (HIV)

Key facts

Sponsor
Viiv Healthcare UK Limited
Participant type
Healthy volunteers
Age range
18-64 years
Gender
Male and Female
Therapeutic area
Diseases [C] - Immune System Diseases [C20]
Trial duration
3 Jun 2026 → ongoing
Decision date (initial)
2026-05-18
Transition trial
No
Low-intervention
No
Rare-disease indication
No
Vulnerable population
No

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

human immunodeficiency virus (HIV)

VersionLevelCodeTermSystem organ class
28.0 LLT 10068341 HIV-1 infection 10021881

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Viiv Healthcare UK Limited

Sponsor organisation
Viiv Healthcare UK Limited
Address
79 New Oxford Street
City
London
Postcode
WC1A 1DG
Country
United Kingdom

Scientific contact point

Organisation
Viiv Healthcare UK Limited
Contact name
EU GSK Clinical Trials Call Center

Public contact point

Organisation
Viiv Healthcare UK Limited
Contact name
EU GSK Clinical Trials Call Center

Locations

1 EU/EEA country · 1 investigational sites

By country

CountryMS statusPlanned subjectsSites
Netherlands Ongoing, recruiting 9 1
Rest of world 0

Investigational sites

Netherlands

1 site · Ongoing, recruiting
Pharmaceutical Research Associates Group B.V.
Program Management, Van Swietenlaan 6, 9728 NZ, Groningen

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Netherlands 2026-06-03 2026-06-05

Application history

3 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2026-04-06 Netherlands Acceptable
2026-05-18
2026-05-18
2 NON SUBSTANTIAL MODIFICATION NSM-1 2026-06-15 Netherlands Acceptable
2026-05-18
2026-06-15
3 SUBSTANTIAL MODIFICATION SM-1 2026-06-26 Netherlands Acceptable 2026-07-06